Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The MHRA intends to drop around 300 roles as it faces a financial crunch after leaving the EU and other pressures.
MHRA Must Seize UK Digital And Diagnostics Opportunity: ABHI Perspectives On Enabling Regulation – Part 2
IVD and healthtech industry representatives give their views on how the future UK medtech system can be shaped to be agile and responsive to patients’ needs, mindful that the regulator must deliver a standalone regulatory system and functional UKCA marking in less than two years.
The fragility of start-ups belies their value in medtech innovation, and they do not need unnecessary regulatory complications.
The UK devices regulator will prioritize innovation, global best practice and enhanced patient safety and the patient voice, MHRA board chairman Stephen Lightfoot said during the ABHI’s spring regulatory conference. New fees for industry are also on the cards.
Higher Medtech Regulatory Salaries In The EU, Longer Recruitment Times And A Candidate-Driven Market
There are some golden career opportunities for medtech regulatory candidates right now. In this preview article to a longer interview piece, Elena Kyria of Elemed explains what these are and how firms with open positions can respond.
Fit For The Future: Industry Gets Involved As UK Medtech And Digital Health Care Regulation Reaches Turning Point
The MHRA is in listening mode as it gathers feedback to shape the UKCA marking for medical devices. That, and how the agency precisely will oversee UK device regulation in the future, are front of mind for industry.
The UK’s new medical device registration system, one element of the post-Brexit transition being overseen by the MHRA, is going more or less to plan in the early stages of the standstill period.
Waiting until the grace period expires before making a product application under the EU MDR or IVDR is a gambit that could easily misfire, TEAM-NB warns.
The end of the UK’s Brexit transition was the beginning of its new relationship as a “third country” with the EU.
There can be no such thing as a COVID dividend, but the renewed digital push and momentum for health system change perhaps come closest.
COVID-19 has forced a rethink in how care should be delivered. Healthcomms Consulting partner Dan Jones says it is an opportunity that must not be squandered.
Not only might each day feel like Groundhog Day now – with COVID-19 limiting everyone’s activities. But early 2021 puts the EU medtech sector in a similar place to early 2020. So what has changed?
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.